Core Viewpoint - The company, Jiukang Biotechnology, has evolved from a代理商 to a leading player in the IVD (in vitro diagnostics) industry in China, focusing on innovation and precision diagnosis to drive future growth [2][3]. Group 1: Company Development - Jiukang Biotechnology started as an代理商 for an international IVD brand and quickly gained recognition, becoming a service supplier for the national quality control products [3]. - The company has maintained a strong client base, with over 70% of top-tier hospitals in China being loyal customers [3]. - The company has significantly increased its R&D investment, with R&D accounting for 21% of sales revenue in the first three quarters of 2025, up from 14% in the same period of 2024 [3]. Group 2: Product Innovation - R&D efforts are focused on new products in areas such as pathology, chemiluminescence, and coagulation, leading to an increase in medical device registrations and patents [4]. - The company has launched new products, including a high-speed fully automated chemiluminescence immunoassay analyzer and a biochemical analyzer, enhancing its competitive edge in the market [4]. - Jiukang's first AI project, a prostate cancer AI interpretation software, has been developed and validated, with plans to expand into smart pathology products [4]. Group 3: Strategic Partnerships - The company aims to become a platform enterprise in the IVD sector, collaborating with leading international firms to leverage their strengths and expand into global markets [5]. - A strategic partnership with Abbott began in 2013, allowing Jiukang to share its patented processes for global product production, resulting in profit-sharing [6]. - In 2020, a significant partnership with China National Pharmaceutical Group (Sinopharm) was established, enhancing sales channels and accelerating growth, with Sinopharm becoming the largest shareholder [6]. Group 4: Industry Trends - The IVD industry in China is rapidly developing, with significant growth potential driven by medical reform and innovation [7]. - The industry is expected to undergo a transformation towards high-quality upgrades, with a focus on value competition rather than price competition [7]. - Emerging technologies such as molecular diagnostics and AI-assisted diagnostics are anticipated to become core competitive advantages, with an emphasis on domestic alternatives in high-end markets [7].